Werewolf Therapeutics, Inc. — Form 8-K Summary
Report date: November 3, 2023. This Form 8-K furnished Regulation FD disclosure and reported other events concerning preliminary clinical data for WTX-124, the company’s lead IL-2 INDUKINE candidate. The filing does not provide a financial reporting period or updated financial statements.
Business Context and Clinical Program
Werewolf is developing WTX-124 for patients with advanced or metastatic solid tumors. The ongoing, multicenter Phase 1/1b WTX-124x2101 trial is evaluating WTX-124 as monotherapy and in combination with pembrolizumab in patients who have failed standard-of-care treatment, including checkpoint inhibitor therapy.
The preliminary data, collected through October 18, 2023, covered 16 heavily pretreated patients in the first four monotherapy dose-escalation cohorts: 1 mg, 3 mg, 6 mg and 12 mg.
Key Clinical and Operating Metrics
- WTX-124 was generally well tolerated at doses up to and including 12 mg in the outpatient setting.
- All treatment-emergent adverse events were Grade 1 or Grade 2; arthralgias and fatigue were the most common events.
- No vascular leak syndrome, dose-limiting toxicities, treatment-related serious adverse events or treatment-related study discontinuations were observed in the reported cohorts.
- WTX-124 was administered intravenously once every two weeks.
- Pharmacokinetic results were described as expected, with evidence of a wide therapeutic index supporting continued dose escalation.
- Biomarker activity, including CD8+ T-cell and natural killer-cell proliferation and activation in the tumor microenvironment, was observed at the 6 mg and 12 mg dose levels.
- Among five patients treated at 12 mg, one achieved an unconfirmed partial response, one had a restaging scan consistent with a partial response as of November 1, 2023, and one other patient showed evidence of antitumor activity.
The filing provides no revenue, profit or loss, cash flow, cash balance, margin, debt, liquidity or other financial metrics.
Material Changes and Outlook
- Dose escalation was ongoing in both the monotherapy and combination-therapy arms.
- The 18 mg monotherapy cohort was fully enrolled as of the filing date.
- Additional monotherapy dose-escalation data were expected to inform selection of a recommended dose for expansion.
- Werewolf expected to open monotherapy expansion arms in the first half of 2024.
Risks, Contingencies and Unusual Items
The reported results are preliminary and from a small, early-stage patient population. The company cautioned that preliminary clinical data may not predict results in the remainder of the trial or in future trials. Key risks include clinical-development and enrollment uncertainties, timing and availability of trial results, regulatory and investigational new drug application requirements, the potential failure of preclinical or early clinical results to predict later outcomes, and the company’s ability to obtain sufficient cash to fund operating and capital requirements.
Exhibits 99.1 and 99.2 contain the related press release and investor presentation. The clinical disclosures were furnished under Regulation FD and Item 8.01 rather than presented as financial results.
Investor Verification Checklist
- Verify subsequent safety, efficacy and enrollment data for the WTX-124x2101 trial, including whether the reported partial responses were confirmed.
- Assess whether dose escalation and the planned first-half-2024 expansion arms proceeded on schedule.
- Review the company’s latest Form 10-Q and subsequent filings for cash runway, funding requirements, operating losses and liquidity.
- Review the full adverse-event, pharmacokinetic and biomarker datasets in Exhibits 99.1 and 99.2.
- Consider whether later clinical results validate the preliminary proof-of-mechanism and proof-of-concept conclusions.